AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...

Isomorphic Labs, launched in 2021 with Google DeepMind, unveiled its newest joint AI offering AlphaFold 3, an AI model that was developed by Isomorphic Labs and Google DeepMind. According to ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

Isomorphic Labs Inc., a healthcare startup that spun out of Alphabet Inc. in 2021, today announced that it has closed a $600 million funding round. OpenAI backer Thrive Capital led the investment. It ...

Experts have been raising concerns about “AI washing.” One of these experts, futurist Bernard Marr, has said that AI washing “involves exaggerating the capabilities of a product or service that is ...

Even though AI-designed drugs aren’t yet a household term for FDA-approved, commercially available therapies, they are a reality in clinical development pipelines. In spring 2024, CBER reported more ...

(Reuters) -U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical, deepening their use of artificial intelligence ...

A new approach to drug design can deliver medicine directly to the gut in mice at significantly lower doses than current inflammatory bowel disease treatments. The proof-of-concept study, published ...

Cyclotides and cyclic peptides represent a promising class of bioactive molecules for modern drug design. Their cyclic backbones, often reinforced by disulfide bonds in a cystine knot, confer ...

Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. Nimbus Therapeutics and Eli Lilly announce their ...

Computational methods have revolutionised drug design by integrating molecular dynamics simulations with advanced free energy calculations. This approach allows researchers to predict binding ...

TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...